EICHOR
● Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Condition: Microvascular Inflammation · Sponsor: Biogen
About this study
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI is a type of injury to small blood vessels in the transplanted kidney and may be a sign of rejection by the body. It can lead to serious kidney problems over time. In many cases, MVI is caused by antibodies that attack the transplanted kidney. But in some people, MVI happens without these antibodies. This type of MVI is called isolated MVI. There are currently no approved treatments for isolated MVI. The main goal of the study is to learn about the effect felzartamab has on inflammation in the transplanted kidney. The main question researchers want to answer is: • How many participants have no signs of active inflammation in the transplanted kidney after 24 weeks of treatment with felzartamab? Researchers will also study how felzartamab affects kidney function, immune activity, and overall health. They will monitor safety through kidney biopsies, lab tests, and by recording adverse events throughout the study. Adverse events are health problems that may or may not be caused by the study drug. The study will be done in 2 parts as follows: * Participants will be randomly assigned to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * In Part A, participants will receive their assigned drug for 24 weeks. Neither the re…
This description comes directly from the study's public registry record.
Talk to the study team
US Biogen Clinical Trial Center · 866-633-4636 · clinicaltrials@biogen.com
Global Biogen Clinical Trial Center · clinicaltrials@biogen.com
Always discuss trial participation with your own doctor first.
Locations (42)
| Loma Linda University Medical Center | Loma Linda, California, United States | Recruiting |
| Keck Hispital of University of Southern California (USC) | Los Angeles, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Providence St. Joseph Hospital Orange | Orange, California, United States | Recruiting |
| Sutter Health - California Pacific Medical Center | San Francisco, California, United States | Recruiting |
| University of California San Fransisco (UCSF) Medical Center | San Francisco, California, United States | Recruiting |
| The University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| University of Michigan Medical Center | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Cooperman Barnabas Medical Center | West Orange, New Jersey, United States | Recruiting |
+ 30 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219043